Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS-3: Myo-Inositol for ROP in Preterm Infants
NCT01954082Phase 3Terminated
- Sponsor
- NICHD Neonatal Research Network
- Start
- Apr 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in retinopathy of prematurity (ROP) comparing myo-Inositol with Placebo (2 arms). Primary endpoint: Number of Participants With Unfavorable Outcome, Defined as Severe Retinopathy of Prematurity (ROP) or Death Prior to Reaching Acute/Final ROP Status. Started Apr 2014; status: terminated.
02
Drugs
myo-inositol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT01954082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01954082.